

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-47. (cancelled)

48 (currently amended). A method for treating ~~or preventing~~ a congenital mitochondrial disease selected from the group consisting of ~~MELAS, LHON, MERRIF, MNGIE, NARP, PEO,~~ Mitochondrial Encephalomyopathy, Lactic Acidemia, and stroke like episodes; Lerber's Hereditary Optic Neuropathy; Myclonic Epilepsy and "Ragged Red" (muscle) Fibers; Mitochondrial neurogastrointestinal encephalomyopathy; Neurogenic muscle weakness, Ataxia and Retinitis Pigmentosa; Progressive External Ophthalmoplegia; Leigh's Disease; and Kears-Sayres Syndrome in a mammal comprising administering to said mammal in need of such treatment ~~or prevention~~ an effective amount of a pyrimidine nucleotide precursor.

49 (currently amended). A method for treating ~~or preventing~~ Alzheimer's Disease in a mammal comprising administering to said mammal in need of such treatment ~~or prevention~~ an effective amount of a pyrimidine nucleotide precursor.

50 (currently amended). A method for treating ~~or preventing~~ Huntington's Disease in a mammal comprising administering to said mammal in need of such treatment ~~or prevention~~ an effective amount of a pyrimidine nucleotide precursor.

51 (currently amended). A method for treating ~~or preventing~~ a neuromuscular degenerative disease in a mammal comprising administering to said mammal in need of such treatment ~~or prevention~~ an effective amount of a pyrimidine nucleotide precursor.

52 (previously presented). A method as in claim 51 wherein said neuromuscular degenerative disease is selected from the group consisting of muscular dystrophy, myotonic dystrophy, chronic fatigue syndrome and Friedreich's Ataxia.

53 (currently amended). A method for treating ~~or preventing~~ pathophysiological consequences of mitochondrial respiratory chain dysfunction selected from the group consisting of developmental delay in cognitive, motor, language, executive function and social skills in a mammal comprising administering to said mammal in need of such treatment ~~or prevention~~ an effective amount of a pyrimidine nucleotide precursor.

54 (currently amended) A method for treating ~~or preventing~~ pathophysiological consequences of mitochondrial respiratory chain dysfunction selected from the group consisting of optic neuropathy, autonomic neuropathy, neurogenic bowel dysfunction, sensorineural deafness, neurogenic bladder dysfunction and migraine in a mammal comprising administering to said mammal in need of such treatment ~~or prevention~~ an effective amount of a pyrimidine nucleotide precursor.

55 (currently amended). A method for treating ~~or preventing~~ pathophysiological consequences of mitochondrial respiratory chain dysfunction selected from the group consisting of renal tubular acidosis, dilating cardiomyopathy and lactic acidemia in a mammal comprising administering to said mammal in need of such treatment ~~or prevention~~ an effective amount of a pyrimidine nucleotide precursor.

56 (currently amended). A method as in claim 53 wherein said developmental delay is pervasive developmental delay or ~~PDD-NOS~~ pervasive developmental delay – not otherwise specified.

57 (previously presented). A method as in claim 53 wherein said developmental delay is Attention Deficit/Hyperactivity Disorder.

58 (previously presented). A method as in claim 53 wherein said developmental delay is Rett's Syndrome.

59 (previously presented). A method as in claim 53 wherein said developmental delay is autism.

60 (withdrawn). A method for reducing side effects of cytotoxic cancer chemotherapy agents by administering a pyrimidine nucleotide precursor, where said cytotoxic chemotherapy agent is not a pyrimidine nucleoside analog.

61 (withdrawn). A method as in claim 60 wherein said side effects of cytotoxic cancer chemotherapy are selected from the group consisting of peripheral neuropathy, chemotherapy-induced menopause, chemotherapy-associated fatigue and depressed appetite.

62 (previously presented). A method as in claim 48 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

63 (previously presented). A method as in claim 49 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

64 (previously presented). A method as in claim 50 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

65 (previously presented). A method as in claim 51 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

66 (previously presented). A method as in claim 53 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

67 (previously presented). A method as in claim 54 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

68 (previously presented). A method as in claim 55 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.

69 (withdrawn). A method as in claim 60 wherein said pyrimidine nucleotide precursor is 2',3',5'-tri-O-acetyluridine.